## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($982.06)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Scotiabank remains bullish on Eli Lilly and Company (LLY)**
- Source: MSN | 20251216T040803 | Bullish | Relevance: 100%
- Scotiabank reiterates its Outperform rating on Eli Lilly and Company (LLY). The firm emphasizes that despite the current valuation, significant potential remains due to the anticipated launch of multiple new products across large therapeutic areas, particularly with the expanding market of obesity drugs like Zepbound.

**2. American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251215T080815 | Bullish | Relevance: 100%
- American Trust significantly increased its stake in Eli Lilly and Company (NYSE:LLY) by 147.1% during the second quarter, bringing its total holdings to 6,122 shares valued at approximately $4.77 million. This move comes as Eli Lilly reported strong earnings, exceeding analyst expectations, and provided optimistic future guidance. Other institutional investors have also shown increased interest, with a substantial 82.53% of the company's stock now owned by institutional investors.

**3. Scotiabank Remains Bullish on Eli Lilly and Company (LLY)**
- Source: Insider Monkey | 20251215T224600 | Bullish | Relevance: 99%
- Scotiabank has reiterated its Buy rating on Eli Lilly and Company (LLY) with a $1,165.00 price target, following positive Phase 3 clinical trial results for its investigational drug retatrutide. Retatrutide, a triple hormone receptor agonist, demonstrated significant weight loss and osteoarthritis pain relief in adults with obesity or overweight, showing up to an average of 71.2 lbs weight reduction. Eli Lilly anticipates additional Phase 3 trials for retatrutide in obesity and type 2 diabetes to conclude in 2026.

**4. Scotiabank Remains Bullish on Eli Lilly and Company (LLY)**
- Source: Finviz | 20251216T035318 | Bullish | Relevance: 97%
- Scotiabank has reiterated a Buy rating on Eli Lilly and Company (LLY) with a price target of $1,165.00, following positive Phase 3 clinical trial results for their investigational drug retatrutide. The drug demonstrated significant weight loss and relief from osteoarthritis pain in adults with obesity or overweight. The company anticipates completing seven additional Phase 3 trials for retatrutide in obesity and type 2 diabetes by 2026.

**5. Obesity data, Kymera and FDA sentiment survey results â€” a BioCentury podcast**
- Source: BioCentury | 20251216T013900 | Somewhat-Bullish | Relevance: 91%
- This BioCentury podcast discusses recent developments in the biotech industry, focusing on new obesity drug data from Eli Lilly, Structure Therapeutics, and Wave Life Sciences, alongside a Pfizer deal in the weight loss space. It also covers Kymera Therapeutics' data for its STAT6 program and the results of BioCentury's industry sentiment survey on the FDA, highlighting concerns about politicization and uncertainty.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($2.06M) |
| Sells | 29 ($190.32M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $190M sold (29 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +6.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 32.1x attractive for 37% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (6 raises, avg +12%). Insider selling cluster ($190.3M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $933.9B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 32.1 |
| Current P/E | 44.1 |
| YoY Growth | 37.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.9% to 1.9% (+6.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.1pp (needs >4.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.27x) but short-term weakness (below SMA20). MACD histogram bearish (-5.58), momentum weakening. RSI neutral at 58. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.89% (CS: 47) | Neutral |
| RSI_14 | 58.2 | Neutral |
| MACD Histogram | -5.58 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.100x | Above |
| vs SMA200 | 1.275x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1041.52
- **Stop Loss:** $982.06 (5.7% risk)
- **Target:** $1160.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 18
- **Position Value:** $18,747.36
- **Portfolio %:** 18.75%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*